Clever Leaves and Biopharmaceutical Research Company to Partner for Landmark Cannabis Research Study in Collaboration with the University of California, Davis

2y
5m read
Summary

Clever Leaves was granted a license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes. To eliminate an additional impediment to the advancement of scientific knowledge around cannabis, this research material will be provided at no cost to Clever Leaves’ research partners. Clever Leaves is a multinational cannabis company with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade cannabinoid processing as the cornerstones of its global cannabis business. Clever Leaves will provide three of its cultivars to BRC for analysis at their facilities. The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States.

Article Preview  The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. NEW YORK, July 27, 2021 — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S., today announced...

Read the full article @ Cannabis Law Report